Ken Herrman (University Hospital Essen, Essen, Germany) discusses a Review in The Lancet Oncology on the role of injectable radiopharmaceuticals with anti-tumour effects.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv